5-Amino-1MQ Dosage Guide

Evidence-based protocols for 5-Amino-1-Methylquinolinium — a small molecule NNMT inhibitor (not a peptide). Oral dosing, NAD+ boosting, fat loss stacking, cycling, and safety.

Compiled by PeptideWiki Editorial Team·Last reviewed February 24, 2026

A leading innovator in research chemicals.

All products HPLC tested

|Exclusive Offer

Coupon

10%

Off

Use our affiliate link and code PEPTIDEWIKI at checkout to unlock your 10% discount, every time you use the code.

Shop Now

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

Research Peptides

5-Amino-1MQ

For research purposes only. PeptideWiki may earn a commission at no extra cost to you.

What Is 5-Amino-1MQ?

5-Amino-1MQ (5-Amino-1-Methylquinolinium) is a small molecule compound — not a peptide — that inhibits the enzyme nicotinamide N-methyltransferase (NNMT). With a molecular weight of approximately 159 Da, it is far smaller than even the smallest peptides (which typically start around 500–1,000 Da). It is sold by peptide vendors and discussed in peptide communities, which leads to frequent misidentification, but it contains no amino acid chain and is not a peptide by any chemical definition.

NNMT is an enzyme overexpressed in adipose (fat) tissue and certain metabolic disorders. It catalyzes the methylation of nicotinamide, consuming S-adenosylmethionine (SAM) and reducing intracellular NAD+ availability. By inhibiting NNMT, 5-Amino-1MQ increases NAD+ levels, enhances cellular energy metabolism, and shifts fat cell activity from lipid storage toward lipid oxidation. This mechanism of action makes it of significant interest for fat loss, body recomposition, metabolic health, and NAD+-mediated longevity pathways.

A key practical advantage of 5-Amino-1MQ is its oral bioavailability. Unlike most peptides, which require reconstitution with bacteriostatic water and subcutaneous injection, 5-Amino-1MQ is taken as a simple oral capsule — no needles, no reconstitution, no refrigeration required for the capsule form. Use our Peptide Dosage if you are working with liquid or injectable forms.

Dosing information in this guide is derived from preclinical studies and community protocols — not from human clinical trials.

Not a peptide. 5-Amino-1MQ is a small molecule quinolinium compound (~159 Da). It appears in this guide series because it is widely sold by peptide vendors and discussed alongside peptides in research communities. Do not attempt to reconstitute or inject oral capsule formulations — oral administration is the standard route.

Key Characteristics:

Small molecule, NOT a peptide — molecular weight ~159 Da; a quinolinium-based compound with no amino acid chain. Frequently miscategorized as a peptide because it is sold by peptide vendors
NNMT inhibitor — inhibits nicotinamide N-methyltransferase, an enzyme overexpressed in adipose tissue that promotes fat storage and reduces NAD+ levels
NAD+ booster — by blocking NNMT, 5-Amino-1MQ preserves and increases intracellular NAD+, supporting energy metabolism, DNA repair, and sirtuin activation
Metabolic shift — redirects fat cell metabolism from lipid storage toward lipid oxidation, supporting fat loss and body recomposition when combined with caloric deficit
Oral bioavailability — taken as a simple oral capsule — no reconstitution, no injection, no bacteriostatic water. This is a major practical advantage over injectable peptides
Adipose tissue selectivity — NNMT is most highly expressed in white adipose tissue, making the compound’s effects preferentially directed at fat cells

For a complete overview of its mechanism and research, see our full 5-Amino-1MQ profile. New to peptides and research compounds? Start with the Beginner's Guide to Peptides.

How 5-Amino-1MQ Dosage Is Determined

5-Amino-1MQ dosing — expressed in milligrams (mg) per day taken orally — is derived from preclinical animal studies, allometric scaling from rodent models to estimated human equivalent doses, and community experience. No human clinical trials have established an official dosing regimen. The commonly used 50–150 mg daily range is based on translated research data and several years of anecdotal reporting.

Preclinical Studies

Key research by Neelakantan et al. (2017, 2018) and Kraus et al. (2014) investigated NNMT inhibition in rodent models of obesity and metabolic dysfunction. These studies used 5-Amino-1MQ and related NNMT inhibitors at doses of 10–20 mg/kg administered via intraperitoneal (IP) injection in mice. Results demonstrated significant reductions in body weight, adipose tissue mass, and adipocyte size, along with increased NAD+ levels and improved metabolic markers.

Allometric Scaling to Human Doses

Using standard mouse-to-human allometric conversion factors (dividing the mouse dose by approximately 12.3 to account for surface area differences), effective mouse doses of 10–20 mg/kg translate to a human equivalent dose of roughly 50–100 mg per day for a 60–80 kg adult. Community protocols have settled around this range, with 100 mg per day being the most commonly cited dosage.

Community & Practitioner Experience

Over the past several years, 5-Amino-1MQ has gained popularity in the peptide and metabolic optimization community. The 100 mg once-daily oral protocol has emerged as the most widely used regimen based on user reports. Some users titrate up to 150 mg for enhanced fat loss effects, while those focused on NAD+ optimization and longevity often use lower doses of 50–100 mg.

Strength of evidence: Low to Moderate. Preclinical studies consistently show NNMT inhibition reduces adiposity and improves metabolic markers in rodent models. However, no human clinical trials have been published for 5-Amino-1MQ specifically. Dosing protocols are derived from allometric scaling and community consensus. Results are promising but not yet validated in controlled human studies.

Standard 5-Amino-1MQ Dosage Ranges

Because 5-Amino-1MQ is a small molecule taken orally (not an injectable peptide), dosing is straightforward — measured in milligrams per day. Most capsules are sold in 50 mg units. The table below summarizes the commonly used protocols.

By Experience Level

Level	Dose	Frequency	Notes
Beginner	50 mg	Once daily (morning)	Assess tolerance for 1–2 weeks before increasing; effective for NAD+ support at this dose
Intermediate (Standard)	100 mg	Once daily (morning)	Most common “sweet spot” — effective for fat loss and metabolic optimization
Advanced	150 mg	Once daily or split (100 mg AM + 50 mg midday)	For experienced users with confirmed tolerance; monitor liver enzymes
High-dose	200 mg	Split (100 mg AM + 100 mg midday)	Less common; requires medical oversight and regular liver monitoring. Diminishing returns beyond 150 mg for most users

Dosage Selection: Start at 50 mg once daily for the first 1–2 weeks. If well tolerated, increase to 100 mg — this is the dose most users settle on. Doses above 150 mg provide diminishing returns and increase the risk of side effects. Take in the morning to avoid sleep disruption. Unlike injectable peptides, no reconstitution or syringe math is needed for oral capsules.

Calculate Your 5-Amino-1MQ Dose

For oral capsules, dosing is simple — capsules are pre-measured (typically 50 mg each), so no reconstitution or syringe calculations are needed. Simply count capsules to reach your target dose. The table below shows common capsule counts.

Oral Capsule Math:

Capsule size: 50 mg per capsule (most common)
Target dose: 100 mg per day
Capsules per day: 100 ÷ 50 = 2 capsules
Monthly supply needed: 2 capsules × 30 days = 60 capsules

Monthly Supply Table (50 mg Capsules)

Daily Dose	Capsules / Day	30-Day Supply	8-Week Cycle	12-Week Cycle
50 mg	1	30 capsules	56 capsules	84 capsules
100 mg	2	60 capsules	112 capsules	168 capsules
150 mg	3	90 capsules	168 capsules	252 capsules
200 mg	4	120 capsules	224 capsules	336 capsules

Liquid or injectable forms? If you are using a liquid solution or injectable form of 5-Amino-1MQ (less common), use our calculator to determine the exact volume per dose based on concentration.

Skip the Math — Use Our

For liquid or injectable forms, enter your vial size, concentration, and desired dose — get instant calculations with zero manual math.

5-Amino-1MQ Forms & Preparation

Unlike injectable peptides, 5-Amino-1MQ is most commonly used as a pre-made oral capsule. No reconstitution with bacteriostatic water is required for capsule form. Here are the forms available and their preparation requirements.

Available Forms

Oral Capsules (Standard)

Pre-measured capsules, typically 50 mg each. No preparation needed — simply take with water. This is the most common and convenient form. Store at room temperature in a cool, dry place.

Raw Powder

Bulk powder form for users who prefer to fill their own capsules or measure custom doses. Requires a precision scale (accurate to 1 mg) and empty capsule shells. Weigh each dose individually for accuracy.

Liquid Solution (Oral)

Some vendors supply 5-Amino-1MQ as a liquid solution for oral dosing. Concentration varies by vendor. Use a graduated pipette or oral syringe for accurate measurement. Refrigerate after opening.

Injectable Form (Less Common)

Some suppliers offer reconstituted injectable versions. This form is far less common and is not necessary given the compound’s oral bioavailability. If using injectable form, treat it like any research compound — sterile technique, SubQ injection, and proper storage.

Storage

Oral capsules: Store at room temperature in a cool, dry place away from direct sunlight. Shelf life typically 12+ months when sealed. No refrigeration required.
Raw powder: Store in an airtight container in a cool, dry place. Refrigeration extends shelf life but is not strictly necessary. Protect from moisture and light.
Liquid solution: Refrigerate after opening at 2–8°C. Use within 4–6 weeks of opening.
Injectable form: If reconstituted, refrigerate at 2–8°C and use within 4–6 weeks. Follow the same storage protocols as injectable peptides.

No reconstitution needed for capsules. If you are coming from injectable peptides and are used to reconstituting with bacteriostatic water, note that 5-Amino-1MQ capsules require no such preparation. Open the bottle, take your capsules, and store at room temperature. This is one of the compound's key practical advantages.

5-Amino-1MQ Dosage by Goal

5-Amino-1MQ's core mechanism — NNMT inhibition leading to increased NAD+ and enhanced fat oxidation — supports several related goals. The optimal dosage and protocol duration vary depending on the primary objective.

Fat Loss & Body Recomposition

The most common use case. NNMT inhibition shifts adipocyte metabolism from fat storage to fat oxidation, while increased NAD+ enhances overall energy expenditure. Preclinical studies showed significant reductions in body fat and adipocyte size. This is most effective when combined with a caloric deficit and regular exercise.

Dose: 100–150 mg per day (oral)
Frequency: Once daily (morning) or split AM/midday
Duration: 8–12 weeks on, 4 weeks off
Key requirement: Caloric deficit (300–500 kcal below maintenance) and resistance training. 5-Amino-1MQ amplifies results but does not replace fundamentals.

NAD+ Optimization & Longevity

NAD+ is a critical coenzyme involved in cellular energy production, DNA repair, sirtuin activation, and mitochondrial function. NAD+ levels decline with age. 5-Amino-1MQ's NNMT inhibition preserves NAD+ pools through a mechanism distinct from direct NAD+ precursors like NMN or NR. For users focused on NAD+ support rather than aggressive fat loss, a lower dose is often sufficient.

Dose: 50–100 mg per day (oral)
Frequency: Once daily (morning)
Duration: 8–12 weeks on, 4 weeks off
Notes: Lower dose sufficient for NAD+ pathway support. Can be combined with other NAD+ strategies (NMN, NR, exercise, fasting). The NNMT inhibition pathway is complementary to direct NAD+ precursor supplementation.

Tip: For NAD+ optimization, 5-Amino-1MQ works through a different mechanism than NMN or NR. NMN/NR directly provide NAD+ precursors, while 5-Amino-1MQ prevents NAD+ degradation by blocking NNMT. The two approaches are complementary and can be used together.

Metabolic Health & Insulin Sensitivity

Preclinical research suggests NNMT inhibition improves insulin sensitivity and metabolic markers beyond its effects on adiposity. NNMT is implicated in metabolic syndrome, and reducing its activity may improve glucose handling, lipid profiles, and inflammatory markers.

Dose: 100 mg per day (oral)
Frequency: Once daily (morning)
Duration: 8–12 weeks on, 4 weeks off
Monitoring: Fasting glucose, HbA1c, and lipid panel at baseline and end of cycle to track metabolic improvements

Application Tip: Consistency is more important than dose escalation. Taking 100 mg every morning for a full 8–12 week cycle with proper diet and exercise produces better outcomes than sporadic high doses. The metabolic shift from NNMT inhibition is gradual and cumulative.

5-Amino-1MQ Administration Guide

Oral Administration — Primary Route

Morning Dosing

Take your capsule(s) in the morning, ideally within 1 hour of waking. Morning dosing aligns with natural metabolic activity and reduces the risk of insomnia.

Take with Water

Swallow capsule(s) with a full glass of water. Can be taken on an empty stomach or with a light meal. If you experience mild GI discomfort, take with food.

Consistent Daily Timing

Take at the same time each day for consistent blood levels. Set an alarm or pair it with your morning routine (e.g., alongside morning vitamins).

Track Your Response

Keep a log of body weight, measurements, energy levels, and any side effects during your cycle. Take progress photos at weeks 0, 4, 8, and 12 for objective comparison.

Subcutaneous Injection (Alternative Route)

If using an injectable form of 5-Amino-1MQ (less common), follow standard SubQ injection protocol: swab the injection site with alcohol, pinch a fold of skin in the lower abdomen or upper thigh, insert the needle at a 45-degree angle, inject slowly, and dispose of the syringe in a sharps container. Rotate injection sites to minimize irritation.

Daily Protocol Example (Oral)

Morning:

Wake → 5-Amino-1MQ (100 mg with water) → Breakfast (optional, 30–60 min after) → Exercise

Midday (if splitting dose):

50 mg with water before lunch — only for advanced users at 150 mg+ total daily dose. Do not take after 2 PM to avoid sleep disruption.

Evening:

No dosing. Avoid 5-Amino-1MQ in the afternoon or evening due to potential insomnia.

Key rule: Dose in the morning. 5-Amino-1MQ increases metabolic activity and energy levels — taking it later in the day can interfere with sleep. If splitting the dose, take the second portion before 2 PM.

5-Amino-1MQ Cycle Duration & Timing

5-Amino-1MQ is used in defined cycles with off-periods. Cycling allows assessment of sustained results, gives the liver a recovery period, and prevents potential adaptation. The off-period is particularly important given the limited long-term human safety data.

Protocol	Duration	Dose	Notes
Beginner cycle	8 weeks on, 4 weeks off	50–100 mg daily	First-time users; start at 50 mg for week 1–2, then 100 mg for weeks 3–8
Standard cycle	12 weeks on, 4 weeks off	100 mg daily	Most common protocol for fat loss and metabolic optimization; liver monitoring recommended at baseline and week 6
Advanced cycle	12 weeks on, 4 weeks off	150 mg daily	Experienced users with confirmed tolerance; liver enzymes required at baseline, week 6, and end of cycle
NAD+-focused cycle	8–12 weeks on, 4 weeks off	50–100 mg daily	For NAD+ optimization and longevity; lower doses are sufficient for this goal

Time of Day

Once daily: Take in the morning within 1 hour of waking. Do not dose in the afternoon or evening.
Split dosing (150 mg+): Take the first dose in the morning and the second before 2 PM. Never dose after 2 PM to avoid insomnia.
Food timing: Can be taken with or without food. If you experience GI discomfort, take with a light meal.
Consistency: Take at the same time daily for stable blood levels. A missed dose can be taken the same day if before 2 PM; otherwise skip and resume the next morning.

During the Off-Period

Maintain your exercise and nutrition regimen to retain results
Get liver function tests (ALT, AST) to confirm normalization before starting the next cycle
Assess body composition changes objectively (measurements, photos, DEXA if available)
The 4-week off-period is a minimum — extend if liver enzymes are elevated

5-Amino-1MQ Stacking Protocols

5-Amino-1MQ is frequently combined with fat loss peptides and metabolic compounds that work through complementary mechanisms. Because 5-Amino-1MQ targets NNMT at the cellular level, it pairs well with compounds that address appetite, lipolysis, or growth hormone pathways.

5-Amino-1MQ + HGH Fragment 176-191 (NNMT Inhibition + Direct Lipolysis)

HGH Fragment 176-191 is a modified fragment of human growth hormone that directly stimulates lipolysis (fat breakdown) without the growth-promoting or insulin-disrupting effects of full HGH. Combined with 5-Amino-1MQ's metabolic shift from fat storage to fat oxidation, this stack targets fat loss from two complementary angles — cellular metabolic reprogramming plus direct lipolytic stimulation.

Compound	Dose	Frequency	Purpose
5-Amino-1MQ	100 mg oral	Once daily (morning)	NNMT inhibition, NAD+ boost, metabolic shift from fat storage to oxidation
HGH Fragment 176-191	250–500 mcg SubQ	Once or twice daily (fasted)	Direct lipolysis, fat cell breakdown without GH-related side effects

Protocol note: HGH Fragment 176-191 is best administered fasted (at least 2 hours after eating) for maximum lipolytic effect. Morning timing works well — take 5-Amino-1MQ orally and inject HGH Fragment SubQ before breakfast. Maintain a caloric deficit for best results.

5-Amino-1MQ + AOD-9604 (NNMT Inhibition + Fat Metabolism)

AOD-9604 is a modified peptide fragment derived from the fat metabolism region of human growth hormone. It stimulates lipolysis and inhibits lipogenesis (new fat formation) without affecting blood sugar or growth. Paired with 5-Amino-1MQ's cellular metabolic reprogramming, this combination targets fat loss through both systemic fat metabolism modulation and intracellular NNMT inhibition.

Compound	Dose	Frequency	Purpose
5-Amino-1MQ	100 mg oral	Once daily (morning)	NNMT inhibition, metabolic efficiency, NAD+ elevation
AOD-9604	300 mcg SubQ	Once daily (fasted, morning)	Lipolysis stimulation, lipogenesis inhibition, fat metabolism

5-Amino-1MQ + Semaglutide (Metabolic Efficiency + Appetite Suppression)

Semaglutide is a GLP-1 receptor agonist that powerfully suppresses appetite, slows gastric emptying, and reduces caloric intake. Combined with 5-Amino-1MQ's cellular metabolic enhancement, this stack addresses weight management from both the demand side (reduced caloric intake via appetite suppression) and the supply side (enhanced fat oxidation and metabolic efficiency via NNMT inhibition).

Compound	Dose	Frequency	Purpose
5-Amino-1MQ	100 mg oral	Once daily (morning)	NNMT inhibition, fat oxidation enhancement, NAD+ boost
Semaglutide	0.25–2.4 mg SubQ	Once weekly (titrated up slowly)	Appetite suppression, reduced caloric intake, GLP-1 receptor activation

Important: Semaglutide requires careful dose titration over weeks–months and has its own significant GI side effects (nausea, vomiting, diarrhea). Start Semaglutide at the lowest dose and titrate slowly. Do not start both compounds simultaneously — establish tolerance to each one individually first. Semaglutide is a prescription medication in many countries.

Explore more combinations with our Peptide Stack Builder or browse the Top 10 Peptide Stacks guide.

Safety, Side Effects & Contraindications

Limited Human Data: 5-Amino-1MQ has not been tested in published human clinical trials. The safety profile is based on preclinical studies and community reports. While preclinical data is generally favorable, long-term human safety has not been established. Use with caution and medical supervision.

Common Side Effects

Mild and generally transient (reported by a subset of users):

GI discomfort (nausea, mild stomach upset) — most common; usually resolves within the first week or when taken with food
Loose stools or diarrhea — typically mild and temporary
Headache — occasionally reported in the first few days of use

Uncommon:

Elevated liver enzymes (ALT, AST) — documented in some users during extended use; resolve during off-cycle
Insomnia or disrupted sleep — typically caused by dosing too late in the day; morning dosing resolves this
Increased energy or restlessness — a function of enhanced metabolic activity; usually perceived as a benefit

Key point: The most commonly reported side effect is mild GI discomfort, which usually resolves by taking the capsule with food or within the first week of use. Liver enzyme elevation is the primary safety concern warranting monitoring.

Contraindications

Pregnancy and breastfeeding — no safety data exists. Absolutely avoid use during pregnancy or nursing.
Active liver disease — individuals with pre-existing hepatic conditions (hepatitis, cirrhosis, significantly elevated baseline liver enzymes) should not use 5-Amino-1MQ due to the risk of further enzyme elevation.
Children and adolescents — not studied in pediatric populations. Do not use in individuals under 18 years of age.
Concurrent hepatotoxic drugs — if taking medications known to stress the liver (acetaminophen at high doses, statins, certain antibiotics), exercise additional caution and consult your healthcare provider.

Recommended Monitoring

Baseline (before starting): Comprehensive metabolic panel including liver enzymes (ALT, AST), fasting glucose, and lipid panel
Mid-cycle (week 6): Repeat liver enzymes (ALT, AST). If values are more than twice the upper limit of normal, discontinue immediately.
End of cycle: Repeat liver enzymes and metabolic panel to confirm normalization before considering another cycle
Alcohol: Minimize or eliminate alcohol consumption during the cycle to reduce liver stress

When to Stop

Persistent GI distress (nausea, diarrhea) that does not resolve within 1 week
Liver enzymes (ALT, AST) exceeding twice the upper limit of normal
Signs of liver stress — dark urine, jaundice (yellowing of skin or eyes), upper right abdominal pain
Severe insomnia despite morning-only dosing
Any symptom that is new, unexplained, or concerning — discontinue and consult a healthcare provider

Regulatory Status: 5-Amino-1MQ is not FDA-approved for human use. It is not a dietary supplement and is not covered by the Dietary Supplement Health and Education Act (DSHEA). It is classified as a research chemical. It is not a controlled substance. However, regulations vary by jurisdiction — verify your local laws before purchasing.

Common 5-Amino-1MQ Dosing Mistakes

Avoid these common errors to get the most out of your 5-Amino-1MQ protocol:

Expecting rapid, dramatic fat loss without diet or exercise: 5-Amino-1MQ shifts metabolism at the cellular level — it is not a thermogenic fat burner. Without a caloric deficit and regular exercise, visible fat loss results will be minimal regardless of dose.

Skipping the beginner dose and starting at 150 mg: Starting at 50 mg for 1–2 weeks allows you to assess GI tolerance and overall response before escalating. Jumping to a high dose increases the risk of nausea, headache, and GI discomfort.

Dosing late in the day or before bed: 5-Amino-1MQ can increase energy and cause insomnia if taken in the afternoon or evening. Morning dosing is recommended to align with natural metabolic activity and avoid sleep disruption.

Running extended cycles without breaks: Standard protocol is 8–12 weeks on, 4 weeks off. Continuous use without cycling increases the risk of elevated liver enzymes and prevents assessment of sustained results off-compound.

Not monitoring liver enzymes: Baseline liver function tests (ALT, AST) before starting and a mid-cycle check around week 6 are recommended. Elevated liver enzymes are an uncommon but documented concern. Discontinue if values exceed twice the upper limit of normal.

Using 5-Amino-1MQ as a standalone fat loss tool without lifestyle changes: 5-Amino-1MQ enhances metabolic efficiency but is not a replacement for caloric deficit, resistance training, and adequate sleep. Think of it as an amplifier, not a replacement, for fundamentals.

Confusing it with a peptide and attempting to inject capsule contents: 5-Amino-1MQ is a small molecule, not a peptide. Oral capsule contents are formulated for GI absorption and contain fillers, binders, and excipients that are not suitable for injection. Never inject the contents of an oral capsule.

Frequently Asked Questions

Key Takeaways

5-Amino-1MQ is NOT a peptide — it is a small molecule quinolinium compound (~159 Da) that inhibits the enzyme NNMT. It is sold by peptide vendors, which causes frequent confusion.
Standard dose: 100 mg orally once daily in the morning. Start at 50 mg for 1–2 weeks to assess tolerance.
Mechanism: inhibits NNMT, boosting intracellular NAD+ levels and shifting fat cell metabolism from storage to oxidation
Oral bioavailability — no reconstitution, no injections, no bacteriostatic water needed for capsule form. Just take capsules with water.
Typical cycle: 8–12 weeks on, 4 weeks off — monitor liver enzymes at baseline and mid-cycle
Top stacks: 5-Amino-1MQ + HGH Fragment 176-191 (dual fat loss), 5-Amino-1MQ + AOD-9604 (NNMT + fat metabolism), 5-Amino-1MQ + Semaglutide (metabolic efficiency + appetite suppression)
Not a standalone fat loss tool — combine with caloric deficit, resistance training, and adequate sleep for meaningful results
Dose in the morning only — afternoon or evening dosing can cause insomnia and sleep disruption
Limited human safety data — liver enzyme monitoring is recommended. Discontinue if ALT/AST exceed twice the upper limit of normal.
Not FDA-approved — classified as a research chemical, not a dietary supplement. Not covered by DSHEA. Check local regulations.

This article is for educational and informational purposes only. See our Disclaimer.

References

Neelakantan H, et al. “Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.” Biochem Pharmacol. 2018;147:141-152. PubMed
Neelakantan H, et al. “Structure-activity relationship for small molecule inhibitors of nicotinamide N-methyltransferase.” J Med Chem. 2017;60(12):5015-5028. PubMed
Kraus D, et al. “Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.” Nature. 2014;508(7495):258-262. PubMed
Hong S, et al. “Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization.” Nat Med. 2015;21(8):887-894. PubMed
Ulanovskaya OA, et al. “NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink.” Nat Chem Biol. 2013;9(5):300-306. PubMed
Kannt A, et al. “Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance.” Diabetologia. 2015;58(4):799-808. PubMed
Pissios P. “Nicotinamide N-methyltransferase: more than a vitamin B3 clearance enzyme.” Trends Endocrinol Metab. 2017;28(5):340-353. PubMed
Campagna R, et al. “Nicotinamide N-methyltransferase in health and cancer.” Int J Mol Sci. 2021;22(18):9633.

Next Steps

Continue your research with these resources.

Dosage Calculator

Calculate exact doses for liquid or injectable forms based on concentration and vial size.

Open Calculator

AOD-9604 Dosage Guide

Learn dosing protocols for AOD-9604, a popular 5-Amino-1MQ stacking partner for fat loss.

Read Guide

Peptide Directory

Browse all peptides and research compounds with summaries and dosing data.

View Directory